In vivo Bioequivalence study of Ticagrelor Tablet

In vivo Bioequivalence study of Ticagrelor 90 mg Tablet manufactured by Sobhan Daroo Co. on 24 volunteers compared with reference product

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210519051345N1

Enrollment

Registered

2021-06-14

Start date

2021-08-21

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In the present study, no diseases will be examined and products will be administered by healthy volunteers..

Interventions

Intervention group: Healthy volunteers.

Eligibility

Sex/Gender

Male

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Being Healthy without any Heart, liver and kidney diseases

Exclusion criteria

Exclusion criteria: Having any kind of illnesses

Design outcomes

Primary

Measure	Time frame
Plasma Drug Concentration. Timepoint: 0.5-48 hours in predetermined time intervals. Method of measurement: HPLC.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin Zakeri-Milani

Tabriz University of Medical Sciences

pzakeri@tbzmed.ac.ir+98 41 3334 8801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026